Patents Assigned to Genome Pharmaceuticals Institute Co., Ltd.
  • Patent number: 10265352
    Abstract: Lactic acid bacteria having high natural immunity activation ability and infection preventative/therapeutic containing said lactic acid bacteria or elements derived from said lactic acid bacteria, and a food/beverage containing these are provided. Lactic acid bacteria belonging to the genus Lactobacillus that are accession number NITE BP-02005 of the NITE NPMD, lactic acid bacteria having natural immunity activation ability that are these lactic acid bacteria or naturally or artificially mutated lactic acid bacteria thereof, lactic acid bacteria having a base sequence of the 16S rDNA region shown by SEQ ID NO: 1, a natural immunity-activating agent having as an active ingredient these lactic acid bacteria, dead cells of these lactic acid bacteria, or a treatment product of these lactic acid bacteria, an infection preventative/therapeutic containing as an active ingredient a peptide glycan of these lactic acid bacteria, and a food/beverage containing these are disclosed.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: April 23, 2019
    Assignees: GENOME PHARMACEUTICALS INSTITUTE CO., LTD., ANTENNA CO., LTD., THE UNIVERSITY OF TOKYO
    Inventor: Kazuhisa Sekimizu
  • Publication number: 20180243352
    Abstract: Lactic acid bacteria having high natural immunity activation ability and infection preventative/therapeutic containing said lactic acid bacteria or elements derived from said lactic acid bacteria, and a food/beverage containing these are provided. Lactic acid bacteria belonging to the genus Lactobacillus that are accession number NITE BP-02005 of the NITE NPMD, lactic acid bacteria having natural immunity activation ability that are these lactic acid bacteria or naturally or artificially mutated lactic acid bacteria thereof, lactic acid bacteria having a base sequence of the 16S rDNA region shown by SEQ ID NO: 1, a natural immunity-activating agent having as an active ingredient these lactic acid bacteria, dead cells of these lactic acid bacteria, or a treatment product of these lactic acid bacteria, an infection preventative/therapeutic containing as an active ingredient a peptide glycan of these lactic acid bacteria, and a food/beverage containing these are disclosed.
    Type: Application
    Filed: February 4, 2016
    Publication date: August 30, 2018
    Applicants: GENOME PHARMACEUTICALS INSTITUTE CO., LTD., ANTENNA CO., LTD., THE UNIVERSITY OF TOKYO
    Inventor: Kazuhisa Sekimizu
  • Patent number: 8754040
    Abstract: Provided are: a novel compound having a structure different from that of existing drugs; a novel microorganism capable of producing the novel compound; and further; a novel compound effective to a multiple-drug-resistant bacterium. To provide a novel compound having a high therapeutic effect which can be expected to have a low hurdle for practical realization by selecting an intended compound from many candidate compounds based not only on an antibacterial activity but also on evaluation including a therapeutic effect, a cyclic peptide compound shown by the following formula (1) or a pharmaceutically allowable salt thereof and a microorganism with Accession No. NITE BP-870 or a microorganism mutated naturally or artificially therefrom are provided. (In the formula (1), R1 represents an acyl group having 7, 8, or 9 carbon atoms and optionally containing a substituent group; R2 represents a methyl group or a hydrogen atom; and R3 represents an ethyl group or a methyl group.
    Type: Grant
    Filed: May 25, 2011
    Date of Patent: June 17, 2014
    Assignees: Genome Pharmaceuticals Institute Co., Ltd., The University of Tokyo
    Inventors: Kazuhisa Sekimizu, Hiroshi Hamamoto, Kazuhisa Murakami
  • Publication number: 20130203654
    Abstract: Provided are: a novel compound having a structure different from that of existing drugs; a novel microorganism capable of producing the novel compound; and further; a novel compound effective to a multiple-drug-resistant bacterium. To provide a novel compound having a high therapeutic effect which can be expected to have a low hurdle for practical realization by selecting an intended compound from many candidate compounds based not only on an antibacterial activity but also on evaluation including a therapeutic effect, a cyclic peptide compound shown by the following formula (1) or a pharmaceutically allowable salt thereof and a microorganism with Accession No. NITE BP-870 or a microorganism mutated naturally or artificially therefrom are provided. (In the formula (1), R1 represents an acyl group having 7, 8, or 9 carbon atoms and optionally containing a substituent group; R2 represents a methyl group or a hydrogen atom; and R3 represents an ethyl group or a methyl group.
    Type: Application
    Filed: May 25, 2011
    Publication date: August 8, 2013
    Applicants: THE UNIVERSITY OF TOKYO, GENOME PHARMACEUTICALS INSTITUTE CO., LTD.
    Inventors: Kazuhisa Sekimizu, Hiroshi Hamamoto, Kazuhisa Murakami
  • Patent number: 8313779
    Abstract: It is intended to provide an evaluation method and a screening method capable of eliminating a substance that disturbs in vivo kinetics in an individual and capable of simply and easily searching a substance having an action of activating/suppressing an innate immune mechanism without being affected by LPS derived from bacteria, which can be contaminated during the search, as well as a drug and a food for activating/suppressing the innate immune mechanism, and methods of producing the same. The present invention provides a method of evaluating or screening the substance having the action of activating/suppressing the innate immune mechanism using a muscular contraction of an organism having the innate immune mechanism as an indicator, and methods of producing the drug and the food for activating/suppressing the innate immune mechanism.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: November 20, 2012
    Assignees: Genome Pharmaceuticals Institute Co., Ltd., The University of Tokyo, Imagine Global Care Corporation
    Inventors: Kazuhisa Sekimizu, Hiroshi Hamamoto
  • Publication number: 20100111870
    Abstract: It is intended to provide an evaluation method and a screening method capable of eliminating a substance that disturbs in vivo kinetics in an individual and capable of simply and easily searching a substance having an action of activating/suppressing an innate immune mechanism without being affected by LPS derived from bacteria, which can be contaminated during the search, as well as a drug and a food for activating/suppressing the innate immune mechanism, and methods of producing the same. The present invention provides a method of evaluating or screening the substance having the action of activating/suppressing the innate immune mechanism using a muscular contraction of an organism having the innate immune mechanism as an indicator, and methods of producing the drug and the food for activating/suppressing the innate immune mechanism.
    Type: Application
    Filed: April 10, 2008
    Publication date: May 6, 2010
    Applicants: Genome Pharmaceuticals Institute Co. Ltd., THE UNIVERSITY OF TOKYO, IMAGINE GLOBAL CARE CORPORATION
    Inventors: Kazuhisa Sekimizu, Hiroshi Hamamoto